Fresh analysis indicates that patients who come off popular GLP-1 drugs like semaglutide or tirzepatide tend to recover reduced body mass much more quickly than those who end traditional lifestyle regimens.
Published data in a prominent medical journal points out that while overweight individuals frequently drop a large proportion of their total mass while using the jabs, the weight returns at an estimated rate of 0.8 kg per month once they quit.
"People buying these drugs should be aware of the risk of rapid weight regain when the medication ends," warns expert Dr. Susan Jebb.
Such speed of recovery implies a reversion to starting weight within about a year and a half.
Comparing Approaches
The research, which looked at 37 of trials involving over 9,000 of participants, compared the results of these new drugs with other pills.
Scientists emphasize that people who lose weight through diet and exercise typically see a more gradual creep back—around 0.1 kg a month—once they finish.
Explaining the Quick Rebound
Experts believe the mode of action of the injections explains the accelerated regain.
The injections imitate a natural hormone called glucagon-like peptide-1, which helps regulate appetite.
"Artificially providing GLP-1 concentrations far above than the body's typical production may cause the system to produce less of its own natural GLP-1, and could diminish responsiveness to its actions," noted Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this medication means hunger is unsuppressed, making overeating far more likely."
A Lifelong Disease?
Medical guidelines suggest the jabs for people with obesity-related health risks, accompanied by recommended diet and exercise modifications.
Many experts argue that, due to the high risk of relapse, the treatment should be considered ongoing.
This opinion is reinforced by drug manufacturers, who state that the findings "highlight the long-term character of obesity," comparing it to managing conditions like diabetes.
Patient Experiences
Users who have discontinued the medication report a intense return of appetite.
"It was like something that goes on and you're instantly extremely hungry," described one woman.
The struggle is worsened if users have not developed sustainable lifestyle or habit modifications during therapy.
Significant Interest
Recent estimates indicate that millions of people in the UK have tried weight-loss jabs in the past year, with desire continuing to grow.
- Use is higher among women than males.
- The middle-aged demographic shows the greatest level of interest.
- Many obtain the drugs through private healthcare rather than the NHS.
Ultimately, clinicians emphasize that while the jabs are potent agents for shedding pounds, they are not a permanent cure and lasting health benefits likely depends on combined lifestyle changes.
